MSACL 

The Evolution of It: Proteomics, Ovarian Cancer and Experimental Design
Mon 4:00 PM - Track 2: Computational, Statistical, and Epidemiological Considerations for Mass Spectrometry in the Clinical Laboratory
Keith Baggerly
M. D. Anderson Cancer Center
Keith Baggerly

M. D. Anderson Cancer Center
The subtitle of this session is: Why hasn’t MS done it yet? To paraphrase a different response, that depends on what ’it’ is. In this talk, we will present a series of historical variations on this theme from the point of view of a cancer biostatistician. This begins with a broad definition of ’it’ as the diagnosis of occult disease using serum samples, discusses why we thought we could do it in the first place, and then looks at what it turned out to be. We will then discuss the broader lessons learned about experimental design and assay limitations, and the extent to which these lessons still apply.
Email: [email protected]